VIRIDIEN 103.800 € (+13,20 %)
CEGEDIM 9.770 € (+1,45 %)
FDJ UNITED 21.860 € (+0,60 %)
EXOSENS 54.100 € (-2,43 %)
AYVENS 9.270 € (+2,71 %)
ENTECH 8.850 € (+4,61 %)
KLEPIERRE 36.160 € (+1,01 %)
TOTALENERGIES 83.180 € (+0,57 %)
ATOS GROUP 26.640 € (+3,10 %)
INVENTIVA 3.745 € (+5,49 %)
AXA 44.300 € (+2,90 %)
DANONE 66.520 € (+0,76 %)
ASML HOLDING 1 377.200 € (-0,56 %)
AIRBUS 195.640 € (+1,20 %)
PHARMING GROUP 1.142 € (+0,75 %)
SCHNEIDER ELECTRIC 237.450 € (-0,96 %)
SAFRAN 292.700 € (+2,70 %)
METROPOLE TV 11.260 € (+11,26 %)
LVMH 408.050 € (+1,63 %)
ADYEN 847.000 € (+2,32 %)
PROSUS 36.145 € (+2,48 %)
SHELL PLC 46.520 € (+0,01 %)
OCI 4.100 € (+0,20 %)
BNP PARIBAS ACT.A 92.030 € (+5,05 %)
DRONE VOLT 0.206 € (+8,78 %)
ABN AMRO BANK N.V. 41.690 € (+4,83 %)
SOITEC 121.000 € (-3,01 %)
ASM INTERNATIONAL 708.400 € (-1,61 %)
VINCI 111.000 € (+2,02 %)
HAL TRUST 170.800 € (+0,71 %)
SAINT GOBAIN 71.780 € (+2,08 %)
V LANSCHOT KEMPEN 63.800 € (+2,24 %)
EIFFAGE 104.200 € (+1,71 %)
2CRSI 19.170 € (+15,55 %)
MAAT PHARMA 1.026 € (+0,98 %)
ACCOR 49.000 € (+2,47 %)
STIF 19.360 € (-1,58 %)
PUBLICIS GROUPE SA 102.500 € (+1,33 %)
SPIE 45.300 € (+1,12 %)
SBM OFFSHORE 33.580 € (+0,42 %)
ING GROEP N.V. 29.040 € (+4,78 %)
KERING 187.580 € (+4,07 %)
L'OREAL 439.150 € (+1,49 %)
WOLTERS KLUWER 88.940 € (+4,10 %)
ARCADIS 47.000 € (0,00 %)
EUROFINS SCIENT. 88.040 € (+0,92 %)
BE SEMICONDUCTOR 155.900 € (-0,13 %)
HEIJMANS KON 88.300 € (+2,32 %)
WAVESTONE 34.250 € (+1,63 %)
HERMES INTL 1 343.500 € (+2,36 %)
DASSAULT SYSTEMES 25.250 € (+1,08 %)
BOUYGUES 41.990 € (+2,34 %)
EXOR NV 73.500 € (+0,34 %)
ADP 116.600 € (+2,01 %)
BIOPHYTIS 0.032 € (+22,48 %)
VALNEVA 2.565 € (+3,43 %)
ENGIE 23.950 € (+2,70 %)
SOPRA STERIA GROUP 194.700 € (+0,52 %)
MEDIANTECHNOLOGIES 3.765 € (+0,94 %)
SOCIETE GENERALE 64.590 € (+4,94 %) |
15/10/2026 13:35
OrbiMed Raises $3 Billion Across Global and Asia Private Equity FundsEQS-News: OrbiMed / Key word(s): Private Equity NEW YORK, Oct. 15, 2026 /PRNewswire/ -- OrbiMed, a leading global healthcare investment firm, is pleased to announce that it has raised $3 billion in commitments for two new private equity funds: OrbiMed Private Investments X and OrbiMed Asia Partners VI.
OrbiMed Private Investments X raised over $1.9 billion to invest in U.S. and European life sciences venture capital opportunities. OrbiMed Asia Partners VI raised over $1 billion to invest in healthcare growth equity and venture capital opportunities across Asia. Both funds seek to build leading healthcare companies focused on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. "There has never been a more exciting time to invest in life sciences innovation," said Carl Gordon, a managing partner of OrbiMed. "AI, a proliferation of new therapeutic modalities and China's emergence as a biotechnology powerhouse are expanding the opportunities to develop transformative treatments. We look forward to helping entrepreneurs turn these advances into leading healthcare companies." OrbiMed is led by 20 partners and supported by a team of over 150 professionals with complementary expertise in company incubation, strategy, operations and finance. The firm operates from 12 global locations across key healthcare markets. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. "We are grateful for the continued support of our many long-standing investors," said Carter Neild, a managing partner of OrbiMed. "We will work tirelessly over the coming years to meet their high expectations." About OrbiMed
![]() 15.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2416642 15.10.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière

